SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (847)6/23/1997 8:27:00 PM
From: John Metcalf   of 6136
 
Thanks for the information, Dave: "total viracept scripts = 5,197 for the week ended 6/13 - down 3.5% from previous week. Both new prescriptions and refills were down. New prescriptions were off 10% to 2,710 from 3,013."

Some comments: 1) Since Viracept is packaged with dosage for 30 days in one bottle, a nine-week moving average (two months) is necessary to evaluate script re-fill trend. 2) The run-rate of new prescriptions is 140,000 per year, when you annualize one week's data. 3) Annualized new scripts based on two-week data is 150,000. 4) At $5,650 per year, AGPH is adding $780 - $880 million in annual revenue, assuming that the new consumers acheive desired benefits from Viracept.

Is this what you meant by "positive spin"?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News